Related Experiment Video
Updated: Feb 1, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
New Challenges for Hypertension Treatment.
Martín Rosas-Peralta1, Gladys Marcela Jiménez-Genchi2
1Jefe de Área Médica, Programa "A todo Corazón-Código Infarto", Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
The 2017 ACC/AHA guidelines redefined hypertension, potentially doubling diagnoses. Careful patient selection is crucial for effective drug therapy in managing high blood pressure and reducing cardiovascular risks.
Area of Science:
- Cardiology
- Public Health
Background:
- Hypertension affects millions in Mexico and the US.
- The 2017 ACC/AHA guidelines redefined hypertension diagnosis to ≥130/80 mmHg.
- This reclassification significantly increases the number of individuals potentially classified as hypertensive.
Purpose of the Study:
- To review current blood pressure targets for hypertension.
- To discuss medical therapies for hypertension in the modern era.
- To emphasize individualized treatment strategies based on patient risk profiles and comorbidities.
Main Methods:
- Literature review of current hypertension guidelines and therapeutic approaches.
- Analysis of the impact of the 2017 ACC/AHA hypertension classification.
- Consideration of patient-specific factors in treatment selection.
Main Results:
- The new hypertension classification may lead to overdiagnosis and overtreatment.
- Real-world evidence suggests caution in initiating drug therapy.
- Individualized treatment is essential, considering patient comorbidities and risk.
Conclusions:
- Careful patient selection is vital when considering drug therapy for hypertension.
- Treatment strategies should be tailored to individual patient characteristics.
- Managing hypertension effectively is crucial for reducing cardiovascular morbidity and mortality.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension I: Introduction

